TB-500
TB-500 is a commercial name used for synthetic thymosin beta-4 or related synthetic peptide products studied mainly in animal and cell-culture models for effects on cell migration, angiogenesis, and tissue repair, with a 2026 scoping review finding no human interventional studies of TB-500 itself in musculoskeletal conditions.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
The parent molecule, thymosin beta-4, binds monomeric G-actin and regulates the pool of actin available for polymerization, a process central to cell motility and migration during tissue repair. Research on thymosin beta-4 and TB-500-labeled products describes effects on VEGF/HIF-related angiogenic signaling, recruitment of endothelial cells, myoblasts, and fibroblasts to injury sites, reduction of NF-κB-driven inflammatory cytokine and chemokine activity, and modulation of extracellular matrix remodeling through effects on collagen deposition and matrix metalloproteinases.
Typical results seen in research
Animal studies (including diabetic rat Achilles tendon, bone fracture, ligament injury, and skin wound models) report improved wound closure, increased angiogenesis markers, and enhanced tissue formation following thymosin beta-4/TB-500 administration. However, a 2026 scoping review found that human evidence is concentrated in ocular/corneal and skin wound settings using thymosin beta-4 itself, and identified no human interventional studies of administered TB-500 for tendon, ligament, muscle, bone, or cartilage conditions — meaning current use for musculoskeletal recovery in humans is not supported by direct clinical trial evidence and rests on animal data.
How it’s commonly used
In research settings, thymosin beta-4/TB-500 has typically been administered by subcutaneous or intramuscular injection over short, injury-specific research cycles; topical or ophthalmic (eye-drop) application has also been used in corneal wound-healing research.
- Applied Sciences · 2026 Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
- FASEB Journal · 2003 The actin binding site on thymosin beta4 promotes angiogenesis
- FASEB Journal · 2004 Thymosin beta4 increases hair growth by activation of hair follicle stem cells
- Joint Diseases and Related Surgery · 2026 Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.